CA3234939A1 - Eukaryotic cells comprising adenovirus-associated virus polynucleotides - Google Patents

Eukaryotic cells comprising adenovirus-associated virus polynucleotides Download PDF

Info

Publication number
CA3234939A1
CA3234939A1 CA3234939A CA3234939A CA3234939A1 CA 3234939 A1 CA3234939 A1 CA 3234939A1 CA 3234939 A CA3234939 A CA 3234939A CA 3234939 A CA3234939 A CA 3234939A CA 3234939 A1 CA3234939 A1 CA 3234939A1
Authority
CA
Canada
Prior art keywords
polynucleotide
cell
polynucleotide encoding
promoter
cap protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3234939A
Other languages
English (en)
French (fr)
Inventor
Michael Goren
Yu Zhao
Alexandros STRIKOUDIS
Darya Burakov
Gang Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of CA3234939A1 publication Critical patent/CA3234939A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA3234939A 2021-10-18 2022-10-18 Eukaryotic cells comprising adenovirus-associated virus polynucleotides Pending CA3234939A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163256730P 2021-10-18 2021-10-18
US63/256,730 2021-10-18
PCT/US2022/078266 WO2023069926A1 (en) 2021-10-18 2022-10-18 Eukaryotic cells comprising adenovirus-associated virus polynucleotides

Publications (1)

Publication Number Publication Date
CA3234939A1 true CA3234939A1 (en) 2023-04-27

Family

ID=84389146

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3234939A Pending CA3234939A1 (en) 2021-10-18 2022-10-18 Eukaryotic cells comprising adenovirus-associated virus polynucleotides

Country Status (11)

Country Link
US (2) US12234472B2 (enExample)
EP (1) EP4419696A1 (enExample)
JP (1) JP2024537896A (enExample)
KR (1) KR20240099288A (enExample)
CN (1) CN118103517A (enExample)
AU (1) AU2022373653A1 (enExample)
CA (1) CA3234939A1 (enExample)
IL (1) IL312124A (enExample)
MX (1) MX2024004647A (enExample)
TW (1) TW202323529A (enExample)
WO (1) WO2023069926A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024263705A2 (en) 2023-06-20 2024-12-26 Regeneron Pharmaceuticals, Inc. Methods for purifying filled adeno-associated virus capsids

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US5985846A (en) 1995-06-07 1999-11-16 Baylor College Of Medicine Gene therapy for muscular dystrophy
US7232899B2 (en) 1996-09-25 2007-06-19 The Scripps Research Institute Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
WO1998054345A1 (en) 1997-05-30 1998-12-03 Baxter International Inc. Mini-adenoviral vector
WO1999053085A2 (en) 1998-04-15 1999-10-21 The Research Foundation Of State University Of New York Selective regulation of adenovirus production
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US5989910A (en) 1998-08-03 1999-11-23 University Of Lausanne Potent genetic switch allowing regulated gene expression in eukaryotic cells
US6423544B1 (en) 1998-12-31 2002-07-23 Chiron Corporation Compositions and methods for producing recombinant virions
MY123548A (en) 1999-11-08 2006-05-31 Shell Int Research Method and system for suppressing and controlling slug flow in a multi-phase fluid stream
DE19955558C2 (de) 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
US6558948B1 (en) 1999-11-23 2003-05-06 Stefan Kochanek Permanent amniocytic cell line, its production and use for the production of gene transfer vectors
ATE440133T1 (de) 2001-02-21 2009-09-15 Cevec Pharmaceuticals Gmbh Pigmentepithelzelle des auges, ihre herstellung und verwendung in der therapie einer augen- oder zns-erkrankung
ES2439874T3 (es) 2002-05-29 2014-01-27 Regeneron Pharmaceuticals, Inc. Sistema de expresión en eucariotas inducible
US8673589B2 (en) 2002-05-29 2014-03-18 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
WO2005106046A1 (en) 2004-05-03 2005-11-10 Stefan Kochanek Modified viral vector particles
DE102005054628A1 (de) 2005-11-16 2007-05-24 Cevec Pharmaceuticals Gmbh Verfahren zur Herstellung von permanenten humanen Zelllinien
WO2007084773A2 (en) * 2006-01-20 2007-07-26 University Of North Carolina At Chapel Hill Enhanced production of infectious parvovirus vectors in insect cells
AU2007249695A1 (en) 2006-05-15 2007-11-22 Paratek Pharmaceuticals, Inc. Methods of regulating expression of genes or of gene products using substituted tetracycline compounds
EP2150617B1 (en) 2007-06-04 2014-10-22 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
US8852926B2 (en) 2007-10-25 2014-10-07 Board Of Trustees Of Southern Illinois University Genetic selection system for identification of MicroRNA target genes
DE102009003439A1 (de) 2009-02-05 2010-08-26 Cevec Pharmaceuticals Gmbh Neue permanente humane Zelllinie
US8734809B2 (en) * 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
WO2011126808A2 (en) * 2010-03-29 2011-10-13 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
US8927514B2 (en) 2010-04-30 2015-01-06 City Of Hope Recombinant adeno-associated vectors for targeted treatment
US9839696B2 (en) 2010-04-30 2017-12-12 City Of Hope Recombinant adeno-associated vectors for targeted treatment
EP2606128B1 (de) 2010-08-16 2014-09-10 CEVEC Pharmaceuticals GmbH Permanente humane amniozyten zellinie zur herstellung von influenzaviren
EP2662451A1 (en) 2012-05-07 2013-11-13 Stefan Kochanek Nucleic acid construct and use of the same
EP2711428A1 (en) 2012-09-21 2014-03-26 Lonza Biologics plc. Site-specific integration
JP6676526B2 (ja) 2013-08-06 2020-04-08 ロンザ バイオロジクス ピーエルシー 組換えタンパク質の生産のための哺乳動物生産細胞の生成のための手段及び方法
GB201322798D0 (en) 2013-12-20 2014-02-05 Oxford Biomedica Ltd Production system
CA2942515C (en) 2014-03-18 2025-12-09 University Of Massachusetts Raav-based compositions and methods for treating amyotrophic lateral sclerosis
BR112017008022A2 (pt) 2014-10-23 2018-02-20 Regeneron Pharmaceuticals, Inc. célula, polinucleotídeo, veículo, e, métodos para modificação de um genoma de células cho e para preparação de uma proteína de interesse.
EP3042952A1 (en) 2015-01-07 2016-07-13 CEVEC Pharmaceuticals GmbH O-glycan sialylated recombinant glycoproteins and cell lines for producing the same
TWI707951B (zh) 2015-04-08 2020-10-21 美商健臻公司 過大腺相關載體之製造
EP3205719A1 (en) 2016-02-15 2017-08-16 CEVEC Pharmaceuticals GmbH Cell lines for producing recombinant glycoproteins with di-antennary n-glycans, methods using the same, and recombinant glycoproteins
GB201603577D0 (en) 2016-03-01 2016-04-13 Oxford Genetics Ltd Promoter
WO2017173043A1 (en) 2016-03-30 2017-10-05 Spark Therapeutics, Inc. Cell line for recombinant protein and/or viral vector production
SG11201807885PA (en) 2016-04-20 2018-10-30 Regeneron Pharma Compositions and methods for making antibodies based on use of expression-enhancing loci
GB2549809C (en) 2016-06-23 2022-11-30 Univ Oxford Innovation Ltd Vector
WO2018031769A1 (en) 2016-08-10 2018-02-15 Lonza Inc. Biopharmaceutical batch recipe review by exception
WO2018146588A1 (en) 2017-02-08 2018-08-16 Friedrich Miescher Institute For Biomedical Research Synp88, a promoter for the specific expression of genes in retinal ganglion cells
JP7467119B2 (ja) 2017-02-17 2024-04-15 ロンザ リミテッド 発現困難タンパク質のための多部位ｓｓｉ細胞
KR102719587B1 (ko) 2017-02-17 2024-10-17 론자 리미티드 아데노-관련 바이러스 생산을 위한 포유동물 세포
CN110419011A (zh) 2017-03-17 2019-11-05 龙沙有限公司 自动化批量数据分析
WO2018175775A1 (en) 2017-03-22 2018-09-27 Dimension Therapeutics Cell culture methods involving hdac inhibitors or rep proteins
EP3382014A1 (en) 2017-03-29 2018-10-03 CEVEC Pharmaceuticals GmbH Recombinant glycoproteins with reduced antennary fucosylation
GB201705927D0 (en) 2017-04-12 2017-05-24 Oxford Genetics Ltd Vector
EP3612635A2 (en) 2017-04-18 2020-02-26 GlaxoSmithKline Intellectual Property Development Limited Methods for adeno-associated viral vector production
CN110892064A (zh) 2017-07-25 2020-03-17 牛津遗传学有限公司 腺病毒载体
EP3441471A1 (en) 2017-08-08 2019-02-13 CEVEC Pharmaceuticals GmbH Use of constitutively active variants of growth factor receptors as selection makers for the generation of stable producer cell lines
EP3456822A1 (en) 2017-09-19 2019-03-20 CEVEC Pharmaceuticals GmbH Inducible aav rep genes
US12123027B2 (en) 2017-10-12 2024-10-22 Ascend Advanced Therapies Limited Life-cycle-defective adenovirus helper viruses, their production and use for producing rAAV
AU2018356538B2 (en) 2017-10-25 2023-09-28 Nouscom Ag Eukaryotic cell line
IL275462B2 (en) 2017-12-22 2026-01-01 Genentech Inc Targeted integration of nucleic acids
GB201800903D0 (en) 2018-01-19 2018-03-07 Oxford Genetics Ltd Vectors
WO2019157239A1 (en) 2018-02-08 2019-08-15 David Kiewlich Plasmid vectors for expression of large nucleic acid transgenes
GB201802122D0 (en) 2018-02-09 2018-03-28 Univ Oxford Innovation Ltd Product and use
GB201814590D0 (en) 2018-09-07 2018-10-24 Oxford Biomedica Ltd Viral vector production system
EP3597172A1 (en) 2018-07-16 2020-01-22 Kao Germany GmbH Hair treatment composition
EP3833745A1 (en) * 2018-08-10 2021-06-16 REGENXBIO Inc. Scalable method for recombinant aav production
EP3841193A1 (en) 2018-08-21 2021-06-30 Lonza Ltd. A process for creating reference data for predicting concentrations of quality attributes
GB201814141D0 (en) 2018-08-30 2018-10-17 Univ Oxford Innovation Ltd Method and compositions for producing a virus
JP7549582B2 (ja) 2018-10-01 2024-09-11 ロンザ リミテッド 予測可能かつ安定な導入遺伝子発現を有するｓｓｉ細胞および形成の方法
AU2019362280B2 (en) 2018-10-17 2026-03-19 Children's Medical Research Institute Nucleic acid molecules and methods for AAV vector selection
GB201816919D0 (en) 2018-10-17 2018-11-28 Glaxosmithkline Ip Dev Ltd Adeno-associated viral vector producer cell lines
WO2020084034A1 (en) 2018-10-26 2020-04-30 F. Hoffmann-La Roche Ag Multispecific antibody screening method using recombinase mediated cassette exchange
CN113396222A (zh) * 2018-12-21 2021-09-14 隆萨沃克斯维尔股份有限公司 腺相关病毒(aav)生产细胞系和相关方法
KR20210108406A (ko) 2018-12-21 2021-09-02 론자 워커스빌 아이엔씨. 바이러스 벡터의 자동화된 생산
AU2019403279A1 (en) 2018-12-21 2021-07-01 Genentech, Inc. Targeted integration of nucleic acids
GB201901571D0 (en) 2019-02-05 2019-03-27 Oxford Genetics Ltd Inducible AAV sysyem
GB201902068D0 (en) 2019-02-14 2019-04-03 Cambridge Entpr Ltd Methods of reactivating proliferative capacity non-proliferative tissues
CN113544509A (zh) 2019-03-08 2021-10-22 牛津遗传学有限公司 选择抗体的方法
SG11202110904PA (en) 2019-04-12 2021-10-28 Ultragenyx Pharmaceutical Inc Engineered producer cell lines and methods of making and using the same
JP7663513B2 (ja) 2019-05-16 2025-04-16 トラスティーズ オブ ボストン ユニバーシティ 調節された合成遺伝子発現システム
AU2020284255A1 (en) 2019-05-30 2022-01-06 Solid Biosciences Inc. Recombinant herpesvirales vector
WO2021127432A1 (en) 2019-12-19 2021-06-24 Lonza Walkersville, Inc. Automated production of viral vectors
CN115315518A (zh) 2020-01-17 2022-11-08 阿斯克肋匹奥生物制药公司 重组aav的生产
GB202001484D0 (en) 2020-02-04 2020-03-18 Oxford Genetics Ltd DNA amplification method
CN115298316B (zh) 2020-02-04 2025-02-14 牛津遗传学有限公司 用于制备腺相关病毒载体的方法
US20230235353A1 (en) 2020-03-19 2023-07-27 Ultragenyx Pharmaceutical Inc. Compositions and methods for reducing reverse packaging of cap and rep sequences in recombinant aav
EP4150097A1 (en) 2020-05-15 2023-03-22 Ivexsol, Inc. Compositions and methods for producing stable viral vector producer cells for cell and gene therapy
CN113699147B (zh) 2020-05-22 2023-06-09 深圳市深研生物科技有限公司 基于四环素和Cumate的共调控序列
US20230279427A1 (en) 2020-07-24 2023-09-07 Regents Of The University Of Minnesota Cell lines for recombinant aav production and aav-implemented protein production
GB202013060D0 (en) 2020-08-21 2020-10-07 Oxford Genetics Ltd Cell line
GB202013057D0 (en) 2020-08-21 2020-10-07 Oxford Genetics Ltd Method of making recombinant aavs
WO2022038367A1 (en) 2020-08-21 2022-02-24 Oxford Genetics Limited Process for making a recombinant aav library
EP4006141A1 (en) 2020-11-25 2022-06-01 CEVEC Pharmaceuticals GmbH Method for the production of aav
KR20230142712A (ko) 2021-02-11 2023-10-11 론자 휴스턴, 아이엔씨. 아데노-연관된 바이러스(aav) 생산
JP2024517104A (ja) 2021-04-19 2024-04-19 オックスフォード ジェネティクス リミテッド Ｃａｒｅエレメントを用いたｄｎａ増幅方法
US20230257831A1 (en) 2021-09-01 2023-08-17 Oxford Genetics Limited Method for determining aav titre
CA3235566A1 (en) 2021-10-18 2023-04-27 Michael Goren Mammalian cells comprising integrated cas9 genes to produce stable integration sites, and mammalian cells comprising stable integration sites and other sites
CN118159660A (zh) 2021-10-18 2024-06-07 瑞泽恩制药公司 多核苷酸的受控转录
WO2023173105A2 (en) 2022-03-10 2023-09-14 Saliogen Therapeutics, Inc. Tetracycline inducer/repressor system and simplified viral particle production

Also Published As

Publication number Publication date
AU2022373653A1 (en) 2024-05-02
JP2024537896A (ja) 2024-10-16
CN118103517A (zh) 2024-05-28
US20230193312A1 (en) 2023-06-22
TW202323529A (zh) 2023-06-16
IL312124A (en) 2024-06-01
MX2024004647A (es) 2024-05-02
US12234472B2 (en) 2025-02-25
WO2023069926A1 (en) 2023-04-27
EP4419696A1 (en) 2024-08-28
KR20240099288A (ko) 2024-06-28
US20250154524A1 (en) 2025-05-15

Similar Documents

Publication Publication Date Title
KR102907773B1 (ko) 인간 대상체에서의 비-노화-관련 청각 손상의 치료를 위한 조성물 및 방법
AU2017315679B2 (en) Compositions and methods for treating non-age-associated hearing impairment in a human subject
EP3880826A1 (en) Use of adeno-associated viral vectors to correct gene defects/ express proteins in hair cells and supporting cells in the inner ear
KR101476010B1 (ko) 고생산성 세포의 수립을 위한 발현 벡터 및 고생산성 세포
US20230304062A1 (en) Controlled transcription of polynucleotides
US20230287460A1 (en) Mammalian cells comprising integrated cas9 genes to produce stable integration sites, and mammalian cells comprising stable integration sites and other sites
KR20220157944A (ko) 인간 대상체에서 비-연령-연관 청각 장애를 치료하기 위한 조성물 및 방법
US20220395582A1 (en) Compositions and methods of inducing differentiation of a hair cell
JP2025087820A (ja) ヒト多能性幹細胞からのミクログリアの迅速かつ確定的な作製
CN109642216A (zh) 通过dna序列划分报告蛋白及其在位点特异性重组中的应用
KR20240035382A (ko) 아데노바이러스 유전자 요법 벡터
AU2018204332A1 (en) Expression cassette
US20250154524A1 (en) Eukaryotic cells comprising adenovirus-associated virus polynucleotides
CN115175559A (zh) 包含人源化pnpla3基因座的非人动物及其使用方法
US7741113B2 (en) Cell-specific molecule and method for importing DNA into osteoblast nuclei
AU2019339404B2 (en) Complement factor h gene knockout rat as a model of C3 glomerulopathy
EA050453B1 (ru) Эукариотические клетки, содержащие аденовирус-ассоциированные вирусные полинуклеотиды
EA052965B1 (ru) Клетки млекопитающих, содержащие интегрированные гены cas9 для производства стабильных сайтов интеграции, и клетки млекопитающих, содержащие стабильные сайты интеграции и другие сайты
TWI923418B (zh) 用於治療人類個體之非年齡相關性聽力障礙的組成物及方法
EA046478B1 (ru) Быстрая и детерминистическая генерация микроглии из плюрипотентных стволовых клеток человека

Legal Events

Date Code Title Description
P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20240717

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240930

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240930

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250925

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250925